Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FSQT1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,043
Award facts
- Contract value 100% obligated
- $34,042.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $34,042.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of Xtandi 40 mg. The award, issued on January 29, 2026, with an ultimate completion date of January 30, 2026, utilizes a firm fixed-price contract type with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established in November 2025 with a $499.999 billion ceiling value extending through December 31, 2036.
The PPV-G GEN V program represents a critical component of the Department of Defense's pharmaceutical supply chain strategy, structured as a $30.3 billion acquisition vehicle designed to provide recurring medical supply support to military healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial performance capability across the federal pharmaceutical distribution sector, supplying an extensive portfolio including oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support diverse healthcare requirements. The company's selection as a prime vendor contractor under this multi-award vehicle reflects its competitive positioning within the unrestricted federal procurement market and its established track record fulfilling specialized pharmaceutical needs for Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FSQT1?
SPE2DR26FSQT1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FSQT1 worth?
The government has obligated $34,043 on SPE2DR26FSQT1.
Is contract SPE2DR26FSQT1 an order under another contract?
Yes. SPE2DR26FSQT1 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQT1 competed?
The extent of competition for SPE2DR26FSQT1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award